Endogenous MPTP-Like Amines in the Brain: Isoquinolines

  • Toshiharu Nagatsu
  • Makoto Naoi
  • Toshimitsu Niwa
  • Mitsuo Yoshida
Part of the Advances in Research on Neurodegeneration book series (ARN, volume 2)


The discovery of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a parkinsonism-producing neurotoxin (Davis et al., 1979; Langston et al., 1983) has greatly contributed to the pathogenesis of Parkinson’s disease. Efforts have been made to find MPTP-like neurotoxins in the brain of parkinsonian patients. MPTP is a precursor neurotoxin, and the oxidized form, by monoamine oxidase type B, N-methyl-4-phenylpyridinium ion (MPP+), is the active neurotoxin (Chiba et al., 1984). It is assumed, therefore, that if any hypothetical MPTP-like neurotoxins exist in the parkinsonian brain they might be oxidized by monoamine oxidase to active neurotoxins.


Tyrosine Hydroxylase Monoamine Oxidase Normal Human Brain Nigrostriatal Dopamine Nigrostriatal Dopaminergic Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Charlton CG, Crowell B Jr (1992): Parkinson’s disease-like effects of S-adenosyl-l-methionine: effects of L-dopa. Pharmacol Biochem Behav 43:423–431PubMedCrossRefGoogle Scholar
  2. Chiba K, Trevor A, Castagnoli N Jr (1984): Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120:574–578PubMedCrossRefGoogle Scholar
  3. Collins MA, Neafsey EJ (1985): Beta-carboline analogues of N-methyl-4-phenyltetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism? Neurosci Lett 55:179–184PubMedCrossRefGoogle Scholar
  4. Davis GCB, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979): Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1:249–254PubMedCrossRefGoogle Scholar
  5. Fields JZ, Albore RR, Neafsey EJ, Collins MA (1992): Inhibition of mitochondrial succinate oxidation — similarities and differences between N-methylated β-carbolines and MPP+. Arch Biochem Biophys 294:539–543PubMedCrossRefGoogle Scholar
  6. Kazita M, Niwa T, Takeda N, Yoshizumi H, Tatematsu A, Watanabe K, Nagatsu T (1993): Presence of N-methyldopamine in parkinsonian and normal human brains. J Chromatogr 613:1–8CrossRefGoogle Scholar
  7. Kikuchi K, Nagatsu Y, Makino Y, Mashino T, Ohta S, Hirobe M (1991): Metabolism and penetration through blood-brain barrier of parkinsonismrelated compounds. 1,2,3,4-tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. Drug Metab Dispos 19:257–262PubMedGoogle Scholar
  8. Langston JW, Ballard P, Tetrud JW, Irwin I (1983): Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980PubMedCrossRefGoogle Scholar
  9. Makino Y, Ohta S, Tachikawa O, Hirobe M (1988): Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: compounds related to Parkinson’s disease. Life Sci 43:373–378PubMedCrossRefGoogle Scholar
  10. Makino Y, Tasaki Y, Ohta S, Hirobe M (1990): Confirmation of the enantiomers of 1-methyl-1,2,3,4-tetrahydroisoquinoline in the mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization. Biomed Environ Mass Spectrom 19:415–419PubMedCrossRefGoogle Scholar
  11. Maruyama W, Nakahara D, Ota M, Takahashi T, Takahashi A, Nagatsu T, Naoi M (1992): N-Methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, (R)-salsolinol, in rat brains: in vivo microdialysis study. J Neurochem 59:395–400PubMedCrossRefGoogle Scholar
  12. Matsubara K, Collins MA, Akane A, Ikebuchi J, Neafsey EJ, Kagawa M, Shiono H (1993): Potential bioactivated neurotoxicants, N-methylated β-carbonium ions, are present in human brain. Brain Res 610:90–96PubMedCrossRefGoogle Scholar
  13. Michel PP, Dandapani BK, Sanchez-Ramos, J, Efange S, Pressman BC, Hefti F (1989): Toxic effects of potential environmental neurotoxins related to 1-methyl-4-phenylpyridium on cultured rat dopaminergic neurons. J Pharmacol Exp Therap 248:842–850Google Scholar
  14. Minami M, Maruyama W, Dostert P, Nagatsu T, Naoi M (1993): Inhibition of type A and B monoamine oxidase by 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines and their N-methylated derivatives. J Neural Transm 92:125–135CrossRefGoogle Scholar
  15. Minami M, Takahashi T, Maruyama W, Takahashi A, Dostert P, Nagatsu T, Naoi M (1992): Inhibition of tyrosine hydroxylase by R and S enantiometers of salsolinol, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline. J Neurochem 58:2097–2101PubMedCrossRefGoogle Scholar
  16. Nagatsu T, Yoshida M (1988): An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primate with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett 87:178–182PubMedCrossRefGoogle Scholar
  17. Naoi M, Matsuura S, Parvez H, Takahashi T, Hirata Y, Minami M, Nagatsu T (1989a): Oxidation of N-methyl-1,2,3,4-tetrahydroisoquinoline into the N-methylisoquinolinium ion by monoamine oxidase. J Neurochem 52:653–655PubMedCrossRefGoogle Scholar
  18. Naoi M, Matsuura S, Takahashi T, Nagatsu T (1989b): An N-methyl-transferase in human brain catalyzes N-methylation of 1,2,3,4-tetrahydroisoquinoline, a pre cursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. Biochem Biophys Res Commun 161:1213–1219PubMedCrossRefGoogle Scholar
  19. Niijima K, Araki M, Ogawa M, Suzuki K, Mizuno Y, Nagatsu I, Kimura H, Yoshida M, Nagatsu T (1991): N-Methylisoquinolinium ion (NMIQ+) destroys cultured mesencephalic dopamine neurons. Biog Amines 8:61–67Google Scholar
  20. Niwa T, Takeda N, Kaneda N, Hashizume Y, Nagatsu T (1987): Presence of tetrahydroisoquinoline and 2-methyl-tetrahydoquinoline in parkinsonian and normal human brains. Biochem Biophys Res Commun 144:1084–1089PubMedCrossRefGoogle Scholar
  21. Niwa T, Takeda N, Tatematsu A, Matsuura S, Yoshida M, Nagatsu T (1988): Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. J Chromatogr 452:85–91PubMedCrossRefGoogle Scholar
  22. Niwa T, Takeda N, Sasaoka T, Kaneda N, Hashizume Y, Yoshizumi H, tatematsu A, Nagatsu T (1989a): Detection of tetrahydroisoquinoline in parkinsonian brain as an endogenous amine by use of gas chromatography-mass spectrometry. J Chromatogr 491:397–403PubMedCrossRefGoogle Scholar
  23. Niwa T, Yoshizumi H, Tatematsu A, Matsuura S, Nagatsu T (1989b): Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. J Chromatogr 493:347–352PubMedCrossRefGoogle Scholar
  24. Niwa T, Takeda N, Yoshizumi H, Tatematsu A, Yoshida M, Dostert P, Naoi M, Nagatsu T (1991): Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoqui-noline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. Biochem Biophys Res Commun 177:603–609PubMedCrossRefGoogle Scholar
  25. Niwa T, Maruyama W, Nakahara D, Takeda N, Yoshizumi H, Tatematsu A, Takahashi A, Dostert P, Naoi M, Nagatsu T (1992): Endogenous synthesis of N-methylsalsolinol, an analogue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in rat brain during in vivo microdialysis with salsolinol as demonstrated by gas chromatography-mass spectrometry. J Chromatogr 578:109–115PubMedCrossRefGoogle Scholar
  26. Ogawa M, Araki M, Nagatsu I, Nagatsu T, Yoshida M (1989): The effect of 1,2,3,4-tetrahydroisoquinoline (TIQ) on mesencephalic dopaminergic neurons inC57BL/6J mice: immunohistochemical studies — tyrosine hydroxylase. Biog Amines 6:427–436Google Scholar
  27. Ohta S, Kohno M, Makino Y, Tachikawa O, Hirobe M (1987): Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline are present in the human brain: relation to Parkinson’s disease. Biomed Res 8:453–456Google Scholar
  28. Ota M, Dostert P, Hamanaka T, Nagatsu T, Naoi M (1992): Inhibition of tryptophan hydroxylase by (R)- and (S)-1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines (salsolinols). Neuropharmacology 31:337–341PubMedCrossRefGoogle Scholar
  29. Sandler M, Bonham-Carter S, Hunter KR, Stern GM (1973): Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man. Nature 241:439–443PubMedCrossRefGoogle Scholar
  30. Strolin-Benedetti M, Dostert P (1992): Monoamine oxidase: from physiology and pathophysiology to the design and clinical application to reversible inhibitors. In: Advances in Drug Research, Vol. 23, Testa B, ed., pp. 65–125. San Diego: Academic PressGoogle Scholar
  31. Strolin-Benedetti M, Bellotti V, Pianezzola E, Moro E, Carminad P, Dostert P (1989): Ratio of the R and S enantiomers of salsolinol in food and human urine. J Neural Transm 77:47–53PubMedCrossRefGoogle Scholar
  32. Suzuki K, Mizuno Y, Yamauchi Y, Nagatsu T, Yoshida M (1992): Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain. J Neural Sci 109:219–223CrossRefGoogle Scholar
  33. Tasaki Y, Makino Y, Ohta S, Hirobe M (1991): l-Methyl-1,2,3,4-tetrahydroisoqui-noline, decreasing in l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J Neurochem 57:1940–1943PubMedCrossRefGoogle Scholar
  34. Yoshida M, Niwa T, Nagatsu T (1990): Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinolines: the behavioral and biochemical changes. Neurosci Lett 119: 109–113PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1994

Authors and Affiliations

  • Toshiharu Nagatsu
  • Makoto Naoi
  • Toshimitsu Niwa
  • Mitsuo Yoshida

There are no affiliations available

Personalised recommendations